Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Martek DHA powder

This article was originally published in The Tan Sheet

Executive Summary

Martek is launching a new powdered form of the omega-3 fatty DHA acid for use in food and beverage products, the firm announces March 20. The company's vegetarian form of DHA (docosahexaenoic acid) powder contains higher amounts of DHA than fish oil powders, "leading to easier food formulation because less powder is needed to achieve desired DHA levels," the Columbia, Md.-based firm states. The new algae-derived DHA powder is available in 10% and 17% DHA concentrations. The introduction of DHA as a food and beverage ingredient follows the business plan outlined by the firm in January, allowing Martek to expand the DHA market beyond infants and effectively make DHA a "lifetime product" (1"The Tan Sheet" Jan. 16, 2006, p. 12)...

You may also be interested in...



Martek Reaches Beyond Infant Formula To Grab Perinatal, Food Markets

Martek Biosciences is supplying DHA for Mission Pharmacal's upcoming Rx perinatal dietary supplement Citracal + DHA, the firm announced during a presentation to investors

Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking

Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.

China VBP, Localization And Other Strategies - How Far And Which Way?

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel